Rigel Pharmaceuticals (RIGL) Stock Analysis & AI Equity Report
Rigel Pharmaceuticals (RIGL) overview
Rigel Pharmaceuticals (RIGL) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 294m and operating profit of USD 125m; the year-end share price was 42.83 USD and market capitalisation was USD 784m. Rigel Pharmaceuticals is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Rigel Pharmaceuticals's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Rigel Pharmaceuticals
Rigel Pharmaceuticals develops and commercializes therapies for hematologic disorders and cancer. Its marketed medicines include TAVALISSE for chronic immune thrombocytopenia, REZLIDHIA for certain acute myeloid leukemia, GAVRETO for RET-driven lung and thyroid cancers, and VEPPANU (vepdegestrant) for specified advanced breast cancer. Rigel also develops clinical candidates, including R289 for myelodysplastic syndromes, and works with pharmaceutical partners on commercialization.
Generate the Rigel Pharmaceuticals report
Rigel Pharmaceuticals is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Rigel Pharmaceuticals and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Rigel Pharmaceuticals
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.